Tsukahara, Masaru
So, Ryuhei
Kitagawa, Kohei
Yada, Yuji
Kodama, Masafumi
Nakajima, Shinichiro
Kishi, Yoshiki
Yamada, Norihito
Takeuchi, Hiroyoshi https://orcid.org/0000-0002-8844-4786
Article History
Received: 16 November 2023
Accepted: 23 July 2024
First Online: 6 August 2024
Declarations
:
: The study protocol was approved by the institutional review board of the Okayama Psychiatric Medical Center. This board also permitted the inclusion of participants who did not actively reject the use of their data. This study was conducted according to the principles of the Declaration of Helsinki.
: We analyzed the existing data. Before conducting this study, we provided participants with the opportunity to opt-out if they did not wish to include their data by uploading information about this study on the websites of the Okayama Psychiatric Medical Center.
: Not applicable.
: Not applicable.
: Masaru Tsukahara has received speaker's fees from Eisai and Sumitomo Pharma. Ryuhei So has received research grants from Japan Society for the Promotion of Science, Ministry of Health, Labor and Welfare, Japan Agency for Medical Research and Development, Osake-no-Kagaku Foundation, Mental Health Okamoto Memorial Foundation, and Kobayashi Magobe Memorial Medical Foundation; and speaker's fees from Otsuka, Nippon Shinyaku, and Takeda. Ryuhei So also reports an employment position at CureApp Inc., which develops software as medical devices. Kohei Kitagawa has received a research grant from Japan Society for the Promotion of Science and Policy-based Medical Services Foundation; speaker's fees from Novartis Pharma and Otsuka; manuscript fees from Japanese Society of Psychiatric Pharmacy, Jiho and Nanzando. Yuji Yada has received speaker's fees from Otsuka and Sumitomo Pharma. Masafumi Kodama declared no conflict of interest. Shinichiro Nakajima has received grants from Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Japan Research Foundation for Clinical Pharmacology, Naito Foundation, Takeda Science Foundation, Watanabe Foundation, Osakeno-Kagaku Foundation, and Astellas Foundation; and an investigator-initiated clinical study grant from Asahi Quality & Innovations; and research support, manuscript fees, or speaker's fees from Sumitomo Pharma, Meiji Seika Pharma, Otsuka, PDR pharma, and MSD. Yoshiki Kishi has received speaker's fees from Janssen, Otsuka, and Sumitomo Pharma. Norihito Yamada has received grants from Ministry of Health, Labour and Welfare, grants and personal fees from Eisai and Otsuka; and personal fees from Daiichi Sankyo, MSD, UCB, Sumitomo Pharma, and Takeda. Hiroyoshi Takeuchi has received grants from Daiichi Sankyo, Novartis Pharma, and Otsuka; speaker's fees from EA Pharma, Eisai, Kyowa, Janssen, Kyowa, Lundbeck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka, Sumitomo Pharma, Takeda, and Yoshitomiyakuhin; and consulting fees from Boehringer Ingelheim, Janssen, Mitsubishi Tanabe Pharma, Ono, and Sumitomo Pharma.